PT2310042E - Uso de pasireotido para o tratamento de hipoglicemia hiperinsulinémica endógena - Google Patents

Uso de pasireotido para o tratamento de hipoglicemia hiperinsulinémica endógena

Info

Publication number
PT2310042E
PT2310042E PT97939409T PT09793940T PT2310042E PT 2310042 E PT2310042 E PT 2310042E PT 97939409 T PT97939409 T PT 97939409T PT 09793940 T PT09793940 T PT 09793940T PT 2310042 E PT2310042 E PT 2310042E
Authority
PT
Portugal
Prior art keywords
pasireotide
treatment
hyperinsulinemic hypoglycemia
endogenous
endogenous hyperinsulinemic
Prior art date
Application number
PT97939409T
Other languages
English (en)
Inventor
Herbert Schmid
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2310042E publication Critical patent/PT2310042E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PT97939409T 2008-07-08 2009-07-07 Uso de pasireotido para o tratamento de hipoglicemia hiperinsulinémica endógena PT2310042E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08159918 2008-07-08

Publications (1)

Publication Number Publication Date
PT2310042E true PT2310042E (pt) 2013-03-11

Family

ID=39876604

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97939409T PT2310042E (pt) 2008-07-08 2009-07-07 Uso de pasireotido para o tratamento de hipoglicemia hiperinsulinémica endógena

Country Status (12)

Country Link
US (2) US9314508B2 (pt)
EP (1) EP2310042B1 (pt)
JP (1) JP5721624B2 (pt)
CY (1) CY1113726T1 (pt)
DK (1) DK2310042T3 (pt)
ES (1) ES2399651T3 (pt)
HR (1) HRP20130145T1 (pt)
PL (1) PL2310042T3 (pt)
PT (1) PT2310042E (pt)
SI (1) SI2310042T1 (pt)
SM (1) SMT201300030B (pt)
WO (1) WO2010003939A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044852A1 (es) * 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
CA2595385C (en) 2005-01-21 2011-01-25 Camurus Ab Pharmaceutical lipid compositions
SI3456340T1 (sl) 2007-01-08 2022-08-31 The Trustees Of The University Of Pennsylvania Antagonisti receptorja za GLP-1 za uporabo pri zdravljenju prirojenega hiperinsulinizma
CA2874367C (en) 2012-05-25 2020-08-18 Camurus Ab Somatostatin receptor agonist formulations
US10711067B2 (en) 2015-03-03 2020-07-14 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
EP3297653B1 (en) 2015-05-22 2021-09-15 The Board of Trustees of the Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with glp-1 antagonists
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
WO2018094404A1 (en) 2016-11-21 2018-05-24 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393050A (en) 1981-04-29 1983-07-12 The Salk Institute For Biological Studies Analogs of extended N-terminal somatostatin
US4703034A (en) * 1986-04-28 1987-10-27 Merck & Co., Inc. Novel cyclic tetrapeptide
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
AR037665A1 (es) * 2001-11-21 2004-12-01 Sod Conseils Rech Applic Analogo de somatostatina y sus usos
MY158342A (en) 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
JP2007518702A (ja) * 2003-11-25 2007-07-12 ノバルティス アクチエンゲゼルシャフト ソマトスタチン類似体処置の効力についてのバイオマーカー
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
DK2310042T3 (da) 2013-03-04
ES2399651T8 (es) 2020-11-18
US20160184388A1 (en) 2016-06-30
US9867864B2 (en) 2018-01-16
EP2310042A1 (en) 2011-04-20
PL2310042T3 (pl) 2013-05-31
US9314508B2 (en) 2016-04-19
WO2010003939A1 (en) 2010-01-14
JP2011527309A (ja) 2011-10-27
CY1113726T1 (el) 2016-06-22
SMT201300030B (it) 2013-07-09
HRP20130145T1 (hr) 2013-03-31
EP2310042B1 (en) 2012-12-05
ES2399651T3 (es) 2013-04-02
JP5721624B2 (ja) 2015-05-20
SI2310042T1 (sl) 2013-03-29
US20110124555A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
PT2310042E (pt) Uso de pasireotido para o tratamento de hipoglicemia hiperinsulinémica endógena
IL253790A0 (en) Factors in the treatment and/or prevention of autoimmune disease and the creation of regulatory t cells
IL210856A0 (en) Combination therapy for the treatment of diabetes and related conditions
EP2212440A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF ADENOCARCINOMES OF DISHES
ZA200902374B (en) Compositions useful for the treatment of diabetes
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
HK1148435A1 (en) Oxadiazoanthracene compounds for the treatment of diabetes
IL210810A0 (en) Compositions for the treatment of pain and/or inflamtion
IL217395A0 (en) Combination therapy for the treatment of diabetes
HK1149322A1 (en) Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
ZA201006827B (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
IL207397A0 (en) Difluorobiphenylamide derivtives for the treatment of ocular hypertension
HK1169993A1 (en) Hsl inhibitors useful in the treatment of diabetes hsl
GB0909297D0 (en) Composition for the treatment of skin conditions
ZA201101303B (en) Kit for the treatment of onychomycosis
IL211189A0 (en) Compounds for the treatment of peripheral neuropathies
GB0822486D0 (en) Compounds for use in the treatment of pain
IL211267A0 (en) Oxadiazole derivatives for the treatment of diabetes
EP2361317A4 (en) USE OF EIF3M FOR THE DIAGNOSIS AND TREATMENT OF CANCER
ZA201101821B (en) 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin deases
GB0719771D0 (en) Dexanabinol in combination with inhibitors of BRAF or MEK for the treatment of melanoma
IL202506A0 (en) Neramexane for the treatment of nystagmus
IT1403064B1 (it) Composizione di sostanze per il trattamento di pazienti con ipercolesterolemia e patologie collegate
ZA201005770B (en) The treatment of damaged skin
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia